Literature DB >> 19382290

Obama administration may flat-line funding for PEPFAR.

Todd Zwillich.   

Abstract

Mesh:

Year:  2009        PMID: 19382290     DOI: 10.1016/s0140-6736(09)60755-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Decision maker priorities for providing antiretroviral therapy in HIV-infected South Africans: a qualitative assessment.

Authors:  April D Kimmel; Norman Daniels; Theresa S Betancourt; Robin Wood; Lisa A Prosser
Journal:  AIDS Care       Date:  2012-02-03

2.  Impact of Patient-Selected Care Buddies on Adherence to HIV Care, Disease Progression, and Conduct of Daily Life Among Pre-antiretroviral HIV-Infected Patients in Rakai, Uganda: A Randomized Controlled Trial.

Authors:  Gertrude Nakigozi; Fredrick E Makumbi; John B Bwanika; Lynn Atuyambe; Steven J Reynolds; Godfrey Kigozi; Fred Nalugoda; Larry W Chang; Valerian Kiggundu; David Serwadda; Maria J Wawer; Ronald H Gray; Moses R Kamya
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

3.  Case management to improve adherence for HIV-infected patients receiving antiretroviral therapy in Ethiopia: a micro-costing study.

Authors:  Elliot A Marseille; Sebastian Kevany; Ismael Ahmed; Getachew Feleke; Bill Graham; Thomas Heller; James G Kahn; Michael Reyes
Journal:  Cost Eff Resour Alloc       Date:  2011-12-20

4.  Health workforce responses to global health initiatives funding: a comparison of Malawi and Zambia.

Authors:  Ruairí Brugha; John Kadzandira; Joseph Simbaya; Patrick Dicker; Victor Mwapasa; Aisling Walsh
Journal:  Hum Resour Health       Date:  2010-08-11

5.  Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia.

Authors:  Elliot Marseille; Mark J Giganti; Albert Mwango; Angela Chisembele-Taylor; Lloyd Mulenga; Mead Over; James G Kahn; Jeffrey S A Stringer
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.